卢美哌隆作为一种新型抗精神病药，可协同作用于5-羟色胺、多巴胺及谷氨酸能系统，其独特的作用机制使得该药不仅能改善精神分裂症患者的阳性症状，亦对阴性症状及抑郁症状有效，常见的不良反应有镇静、头痛、腹泻、口干等，已被美国食品药品监督管理局批准用于治疗成人精神分裂症。本文对卢美哌隆的药理机制及药代动力学、临床研究进展、安全性及耐受性等内容进行了综述。“,”As a novel antipsychotic drug, lumateperone acts synergistically via serotonergic, dopaminergic, and glutamatergic systems to generate efficacy in positive, negative and depressive symptoms as well. Common adverse reactions are sedation, headache, diarrhea, and dry mouth. Lumateperone has been approved by the U.S. Food and Drug Administration for treatment in adult schizophrenic patients. The pharmacodynamic and the pharmacokinetic profiles, evidence of clinical researches, safety and tolerability of Lumateperone are reviewed in this article.